AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients
21.1.2021 13:14:00 EET | Business Wire | Press release
AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study.
“We are pleased to report the achievement of this critical milestone, and AriBio is looking forward to announcing the topline results by the end of Q1’2021. Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial. We are extremely grateful to our study participants, their family members and healthcare professionals who worked tirelessly to complete the primary assessments of the study,” said James Rock, Senior Vice President of Clinical Operations.
AriBio offered an optional 6-month extension phase of the study, where patients could either stay on active drug or be randomized to the low or high dose of active medication. “Notably, over 80% of the patients opted to participate in the extension study, signaling an excellent safety and tolerability profile of AR1001 as well as the overall patients’ positive reaction to the drug. We are encouraged to quickly generate the topline results and to move forward with a global phase 3 program,” said Dr. Matthew Choung, Chief Executive Officer.
AriBio is the first company from South Korea to successfully complete a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Dementia with Lewy Bodies in 2021 and a Phase 3 program for Alzheimer’s disease in 2022.
About AR1001
AR1001 is a first-in-class oral drug with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated notable effects against amyloid plaques and tau proteins via autophagy activation.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of new drugs for neurodegenerative and infectious diseases. AR2001 is the lead candidate for sepsis and COVID-19 treatment, which is scheduled to enter a Phase 1 study in the United States in 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005408/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Goldman Sachs Alternatives Acquires FGI Worldwide12.5.2026 12:00:00 EEST | Press release
FGI Worldwide LLC (“FGI” or the “Company”), a leading provider of working capital financing and trade credit insurance solutions, today announced it has been acquired by the Private Equity business within Goldman Sachs Alternatives. Over its 25-year history, FGI has established a strong reputation as a leader and innovator in asset-based lending and risk mitigation, specializing in multi-jurisdictional working capital solutions that support businesses with flexible financing to drive domestic and global expansion. The acquisition enables FGI to accelerate its growth and expand its suite of financing, risk and Insurtech solutions for clients. In conjunction with the transaction, Sami Altaher, Co-Founder and President of FGI, succeeds David DiPiero as Chief Executive Officer, marking the next chapter in the Company’s evolution. “We are grateful to our team, customers, partners and investors who have made this milestone possible,” said Altaher. “I am incredibly proud of what we have built
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets12.5.2026 11:45:00 EEST | Press release
“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511305446/en/ Antonio Petralia, CEO of Eurosets; Sahara Romero, patient; dr. Mario Andrés Mercado Díaz, Intensive care specialist at the Clínica Shaio in Bogotá; Estefanía Giraldo Bejarano, specialist ECMO nurse at the Clínica Shaio in Bogotá Sahara has lived with a serious heart condition since early adolescence. The first signs of heart failure appeared when she was eleven. “When I was doing simple activities, like gymnastics lessons, I got very tired and experienced pain in my chest
New Research From Infobip Finds Disconnected Data and Systems Prevent Brands From Automating Customer Journeys at Scale12.5.2026 11:39:00 EEST | Press release
Global AI-first cloud communications platform Infobip’s 2026 Customer Experience (CX) Maturity Report reveals a widening gap between communications infrastructure investment and CX performance. With ever-increasing customer expectations, achieving CX maturity is the goal for major global brands. This hinges on how well brands can build experiences on mobile channels. There is a fundamental difference between a simple fraud alert on SMS and a two-way WhatsApp chat that allows customers to act immediately. While 96% of brands automate customer interactions in some way, few are delivering a seamless experience. Only 58% of brands say their channels are fully in sync, and 60% have centralized storage of customer data. But looking closer, only 27% use an orchestration platform, and 50% of brands say their tools are fully API-ready. This means half of brands struggle with connecting tools and data and many don't use a unified platform to build truly seamless experiences. This fragmentation i
Rerouting Alone Could Cost Airlines $8 Billion This Summer, New i6 Group Data Shows12.5.2026 11:00:00 EEST | Press release
Airlines flying European long-haul routes are facing a fuel cost penalty that could exceed $8 billion between May and August 2026, according to a new operational data report released today by i6 Group, a global leader in integrated aviation fuel management technology. The report, “Middle East Conflict: Summer 2026 Outlook,” draws on real fueling transactions captured at nearly 300 airports worldwide by i6's Fusion6 platform and provides insight into the costs of the conflict so far and how it might impact summer travel, based on actual fuel supply and into-plane uplift data. Key Findings $5.6 billion – $8.4 billion: Projected industry-wide rerouting fuel cost, May–August 2026 62.2%: Increase in European airport fuel book stocks (April 2026 vs. April 2025) 415,373 tons: Additional CO2 generated monthly from rerouting in the i6 network alone, or the equivalent of nearly 6,000 extra London–New York round-trip flights per month "The data captures what airlines are paying to fly around clos
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 10:01:00 EEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom